Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Clin Cancer Res. 2014 May 8;20(13):3446–3457. doi: 10.1158/1078-0432.CCR-13-2797

Figure 4. Restoration of the MAPK pathway activity and enhancement of cytokine production by vemurafenib in lymphocytes exposed to PD-L1.

Figure 4

A) PBMCs were primed by mitogen activation to express PD-1. This priming by mitogen activation leads to proliferation of activated T lymphocytes. Then in the presence and absence of vemurafenib, cells were exposed to anti-CD3/antiCD28 or anti-CD3/antiCD28 plus recombinant PD-L1 coated plates for 24 hours. B) Western blot analysis of the MAPK pathway activity in the lymphocytes exposed to the mentioned conditions described in the section A. C) Quantitation of the same Western blot analysis by densitometry. D) ELISA assays were performed in duplicates to detect the concentration of cytokines in the supernatants of lymphocytes primed and treated according to the same experimental settings described in the section A. Error bars are two standard deviations.